Inflation Reduction Act impact on biopharma portfolio strategies
An examination of potential implications for how drug manufacturers manage their portfolios in the wake of the Inflation Reduction Act
Within healthcare, the Inflation Reduction Act (IRA) aims to improve affordability and accessibility by lowering prescription drug prices and out-of-pocket costs for Medicare beneficiaries and extending premium subsidies in the Affordable Care Act’s (ACA) marketplaces.
Sweeping proposals introduced by the act represent some of the most significant healthcare legislation since the ACA by giving Medicare the ability to negotiate drug prices with manufacturers. In this paper, we discuss potential implications of these policies for how drug manufacturers manage their portfolios.
About Healthcare & Life Sciences at KPMG
Dive into our thinking:
Inflation Reduction Act impact on biopharma portfolio strategies
Download PDFExplore more
Meet our team
Subscribe to M&A Spotlight
KPMG Deal Advisory distributes a wide selection of thought leadership that highlights the latest M&A issues and trends.
Subscribe to KPMG Healthcare and Life Sciences Insights
Industry insights and trends, one click away.